Tozorakimab Medicine 04 December 2025 Extended indication LRTD (lower respiratory tract disease), in het Nederlands onderste luchtwegaandoeningen. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Tozorakimab Domain Lung diseases Reason of inclusion Indication extension IND Main indication COPD Extended indication LRTD (lower respiratory tract disease), in het Nederlands onderste luchtwegaandoeningen. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer AstraZeneca Portfolio holder AstraZeneca Mechanism of action Immunosuppression Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date September 2026 Expected Registration November 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Antibiotica en steroïden Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Er zijn nog geen resultaten beschikbaar om een inschatting op te baseren over de therapeutische waarde. Duration of treatment Frequency of administration 1 times a day Dosage per administration single-dose infuus References NCT05624450 (TILIA); Expertopinie Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References vzinfo.nl Additional remarks In 2022 vonden er 36.175 klinische ziekenhuisopnamen plaats vanwege infecties van de onderste luchtwegen. Expected cost per patient per year Cost € 5,000.00 - 12,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References GIPdatabank Additional remarks Op basis van de gemiddelde vergoeding van andere interleukineremmers, zal tokorakimab mogelijk tussen de €5.000 en €12.000 per patiënt per jaar gaan kosten. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Yes Indication extensions COPD indicatie als eerste, LRTD volgt enkele maanden later. References Additional remarks Other information Additional remarks